India, Aug. 19 -- Agenus Inc. (AGEN), a clinical-stage immuno-oncology company developing antibody-based therapies, recently reported financial results for the second quarter ended June 30, 2026, and provided business updates on its BOT+BAL program.
Company Profile
U.S.-based Agenus is focused on developing immuno-oncology therapies designed to activate innate and adaptive immune responses and overcome tumor immune evasion. Its lead program, botensilimab (BOT) plus balstilimab (BAL), is being advanced in multiple cancer indications, including high-risk microsatellite-stable (MSS) colon cancer.
Q2 FY26 Highlights
For the second quarter, Agenus reported net income of $0.6 million, compared with a net loss of $30.0 million in the year-ago ...